ACHIEVE LIFE SCIENCES INC (ACHV) Stock Price, Forecast & Analysis
NASDAQ:ACHV • US0044685008
ACHV Key Statistics, Chart & Performance
The current stock price of ACHV is 4.25 USD. In the past month the price decreased by -19.37%. In the past year, price increased by 37.85%.
ACHV Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ACHV. When comparing the yearly performance of all stocks, ACHV is one of the better performing stocks in the market, outperforming 80.69% of all stocks.
ACHV Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ACHV. ACHV may be in some trouble as it scores bad on both profitability and health.
ACHV Financial Highlights
Over the last trailing twelve months ACHV reported a non-GAAP Earnings per Share(EPS) of -1.38. The EPS decreased by -22.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -100.59% | ||
| ROE | -155.72% | ||
| Debt/Equity | 0.26 |
ACHV Forecast & Estimates
13 analysts have analysed ACHV and the average price target is 15.3 USD. This implies a price increase of 260% is expected in the next year compared to the current price of 4.25.
ACHV Ownership
ACHV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.59 | 396.512B | ||
| AMGN | AMGEN INC | 16.62 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 17.06 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.38 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.74 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.71 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.6 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.97 | 20.691B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACHV
Company Profile
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 25 full-time employees. The firm focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. The company has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.
Company Info
ACHIEVE LIFE SCIENCES INC
22722 29Th Dr. Se, Suite 100
Seattle WASHINGTON V6E 4H1 US
CEO: John Bencich
Employees: 25
Phone: 14256861500
ACHIEVE LIFE SCIENCES INC / ACHV FAQ
What does ACHV do?
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 25 full-time employees. The firm focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. The company has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.
What is the stock price of ACHIEVE LIFE SCIENCES INC today?
The current stock price of ACHV is 4.25 USD. The price decreased by -2.75% in the last trading session.
Does ACHV stock pay dividends?
ACHV does not pay a dividend.
How is the ChartMill rating for ACHIEVE LIFE SCIENCES INC?
ACHV has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does ACHIEVE LIFE SCIENCES INC belong to?
ACHIEVE LIFE SCIENCES INC (ACHV) operates in the Health Care sector and the Biotechnology industry.
What is the Short Interest ratio of ACHIEVE LIFE SCIENCES INC (ACHV) stock?
The outstanding short interest for ACHIEVE LIFE SCIENCES INC (ACHV) is 13.49% of its float.